Early Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a low-grade brain tumour (Grade I or II) located in the brainstem or the upper part of the brain, confirmed by a biopsy (or, for those with a condition called NF1, by the typical appearance of the tumour on scans).
- People whose tumour measures at least 1 cm x 1 cm on an MRI scan.
- People who are already scheduled to receive systemic (whole-body) treatment for their low-grade brain tumour.
- People who have a general health and functioning score of at least 50 out of 100, as rated by their doctor using standard medical scales (people who use a wheelchair but are otherwise up and about may still meet this requirement — confirm with trial site).
- People who are aged between 1 and 21 years old at the time of registration.
- People who are already on a treatment plan are still eligible to be considered for this trial.
Who may not be able to join:
- People who, in their doctor's opinion, would not be able to tolerate the imaging procedures required by the trial.
- People who are pregnant.
- People who weigh less than 8 kilograms.
- People who cannot avoid being in contact with a pregnant woman or an infant for at least 12 hours after receiving the trial injection.
- People who have a history of abnormal kidney function, or whose kidney function test results are significantly outside the normal range at the time of registration.
- People whose tumour started in the spinal cord.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mariam Aboian, MD,PhD, The Children s Hospital of Philadelphia
Phone: 215-510-7661
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Compare change in standardized uptake value parameters (SUVmax and SUVpeak) on metabolic tumor volume in 18F-Fluciclovine PET; Compare changes in pretreatment tumor measurement on MRI in pediatric participants who initiate systemic treatment for LGG
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.